

The logo for the Pennsylvania Perinatal Quality Collaborative (PA PQC). It features the letters 'PA' in white, with the 'A' partially filled by a blue silhouette of the state of Pennsylvania. To the right of this is the text 'PQC' in a large, bold, blue sans-serif font. Below the logo, the full name 'Pennsylvania Perinatal Quality Collaborative' is written in a smaller, red sans-serif font.

**PA PQC**  
**Pennsylvania Perinatal Quality Collaborative**

---

**PA PQC Learning Session**  
**September 3, 2020**

# Collective Progress

---

Robert Ferguson, MPH, Chief Policy Officer  
Jewish Healthcare Foundation

# The PA PQC was Built on Statewide Efforts

---

- Premie Network and AAP
- West Chester University Pilot Study with the Vermont Oxford Network (VON)
- PA PQC Task Force
  - Facilitated by March of Dimes
- PA PQC Advisory and 8 Work Groups (140+ people)



# PA PQC Aims

---

- ✓ Reduce maternal mortality and morbidity
- ✓ Improve Identification of and Care for Pregnant and Postpartum Women with Opioid Use Disorders (OUD)
- ✓ Improve Identification of and Care for Opioid-Exposed Newborns (OEN)

*Thank you!*




**pennsylvania**  
DEPARTMENT OF DRUG AND  
ALCOHOL PROGRAMS



**HENRY L.  
HILLMAN**  
FOUNDATION

# What it Means to be a PA PQC Site



# The PA PQC Called for QI Report Outs & You Submitted:

---

- ✓ **21** SUD QI projects
- ✓ **4** Immediate Postpartum LARC projects
- ✓ **33** NAS QI Projects
- ✓ **37** Maternal Mortality QI Projects (*hypertension or hemorrhage*)

*If can still submit your QI projects!*

# Apply for PA PQC Quality Awards to Support Your QI Work

---

- ✓ PA PQC \$15,000 OUD and NAS QI Sub-Award Application Due by 9/28
- ✓ PA PQC \$9,000 Immediate Postpartum LARC Start-Up Award Application Due by 9/28

# The PA PQC Policy Group Launched an Immediate Postpartum LARC Sub-Group

---

- Improve and learn more about LARC coverage policies among commercial payers
- Clarify some of the operational items related to the Medicaid reimbursement policies.

PA PQC IPLARC pilot sites | family planning providers |  
Medicaid MCOs | commercial payers | state agencies



# The PA PQC Called for Data Submissions & You Submitted:

---

- ✓ 34 sites submitted data on at least one NAS-related measures
- ✓ 17 sites submitted data on at least one OUD-related measures
- ✓ 26 sites submitted data on at least one MM-related measures

*Due 30 days after measurement period!*

## Focus Areas:

- ✓ SUD Screening
- ✓ MAT initiation
- ✓ NAS Hospital LOS (updated guidance)
- ✓ % NAS who received pharmacological interventions (updated guidance)
- ✓ % NAS who received non-pharmacological interventions (updated guidance)

# PA PQC Data Submissions

---

*Due 30 days after measurement period!*

PQC Calendar: <https://www.whamglobal.org/papqc>

## Focus Areas:

- ✓ SUD Screening
- ✓ MAT initiation
- ✓ NAS Hospital LOS (updated guidance)
- ✓ % NAS who received pharmacological interventions (updated guidance)
- ✓ % NAS who received non-pharmacological interventions (updated guidance)

# The PA PQC Called for April-June Surveys & You Submitted:

---

- ✓ 37 sites submitted NAS surveys
- ✓ 42 sites submitted OUD surveys
- ✓ 42 sites submitted MM surveys

# OUD Survey Results

*Baseline compared to April-June 2020*

---

Standardized education materials for OUD/NAS

44% vs. 76%

Used a validated, self-report screening tool for substance use in pregnancy

34% vs. 67%

Clinical order sets for maternal OUD

35% vs. 67%

Provide opioid pharmacotherapy for maternal OUD

54% vs. 69%

# MAT Waiver Training for Women's Health Providers to Help this Structural Measure in Place

---

September 30 from 8:00 a.m. to 12:30 p.m.

<https://www.whamglobal.org/member-content/additional-trainings>

# NAS Survey Results

*Baseline compared to April-June 2020*

---

Nursing staff trained on validated NAS assessments in the past year

59% vs. 76%

Used standardized non-pharmacologic protocols for NAS

68% (Oct.-Dec. 2019) vs. 76%

# Maternal Mortality Survey Results

*Baseline compared to April-June 2020*

---

Respond with unit-standard, stage-based, OB hemorrhage emergency management plan with checklists

68% vs. 90%

Implement QI projects that target disparities in access, treatment, and outcomes?

49% vs. 56%

# Future Directions

---

Robert Ferguson, MPH, Chief Policy Officer  
Jewish Healthcare Foundation



# The PA PQC is Maintaining a Focus on OUD/NAS Key Interventions

---

- Screening all pregnant women for SUD/OUD using validated screening tools
- Establishing clinical pathways for women with OUD, and engaging them in MAT treatment
- Providing access to immediate postpartum contraceptive options, including Immediate Postpartum LARC
- Standardizing non-pharmacologic and pharmacologic NAS care
- Providing home visitation post-discharge for mothers and infants exposed to opioids in partnership with health plans and counties
- Creating a safe environment for the infant by connecting the mom/baby dyad to wrap around supports
- Caring for the mom/baby dyad for 15 months through well-child visits

# The PA PQC is Launching the Moving on Maternal Depression (MOMD) Initiative in the Fall

---

- ✓ Improve maternal depression screening and follow-up
- ✓ Reduce racial disparities


*MOMD Survey Due 9/24*

<https://www.surveymonkey.com/r/58GM9BR>

# The PA PQC is Applying to Become an AIM State in the Fall with a Rollout in 2021

---

- ✓ hemorrhage OR severe hypertension bundle
- ✓ disparities bundle



# 9/3 Learning Objectives

---

- Describe the Change Package and Next Steps for the PA PQC's **Moving on Maternal Depression** (MOMD) initiative
- Describe how to **incorporate depression screening and follow-up** services in prenatal and postpartum office visit workflows
- Discuss examples of how birth hospitals are **responding to implicit bias**
- Describe how to **incorporate standard work and root causes analyses** into your approach to quality improvement in the PA PQC
- Discuss example of how birth hospitals and NICUs have adopted **PA PQC key interventions for maternal OUD or NAS**
- Describe the logistical challenges to **offering immediate postpartum LARC** and examples for how to break through each challenge

# Continuing Education Information

---

In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and The Jewish Healthcare Foundation. The University of Pittsburgh is jointly accredited by the **Accreditation Council for Continuing Medical Education (ACCME)** and the **American Nurses Credentialing Center (ANCC)**, to provide continuing education for the healthcare team. **4.00 hours are approved for this course.**

As a Jointly Accredited Organization, University of Pittsburgh is approved to offer social work continuing education by the **Association of Social Work Boards' (ASWB)** Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. University of Pittsburgh maintains responsibility for this course. Social workers completing this course receive **4.00 continuing education credits.**

# Disclosures

---

No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.

# Disclaimer

---

The information presented at this Center for Continuing Education in Health Sciences program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.